Evidence map›Paper›PMID 34275898›Full record

ArticleJournal of Alzheimer's disease : JAD2021

Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.

Kaito Kawamura, Masakazu Miyajima, Madoka Nakajima, Mitsuyasu Kanai, Yumiko Motoi, Shuko Nojiri, Chihiro Akiba, Ikuko Ogino, Hanbing Xu, Chihiro Kamohara and 5 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05915000 (Alterations of CSF Protein Markers as Prognostic Indicator of the Response to Cerebrospinal Fluid Shunting in Chronic Hydrocephalus in Adults), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05915000 recruitingnot on this map

Alterations of CSF Protein Markers as Prognostic Indicator of the Response to Cerebrospinal Fluid Shunting in Chronic Hydrocephalus in Adults

TypeobservationalSponsorUniversity of ValenciaRan2019 to 2029Enrolled150ConditionsBeta-amiloid and Phospho-tau Proteins in CSF, Ventricular Size After CSF Shunt, Cognitive Impairment and CSF Shunt, Motor Impairment Evolution After CSF ShuntArmsLumbar CSF protein marker determination
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Kaito KawamuraDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Masakazu MiyajimaDepartment of Neurosurgery, Juntendo Tokyo Koto Geriatric Medical Centre, Shinsuna Koto-ku, Tokyo, Japan.
Madoka NakajimaDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Mitsuyasu KanaiDepartment of Neurology, Mihara Memorial Hospital, Ota-cho, Isesaki-shi, Gunma, Japan.
Yumiko MotoiDepartment of Neurology, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Shuko NojiriMedical Technology Innovation Center, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Chihiro AkibaDepartment of Neurosurgery, Juntendo Tokyo Koto Geriatric Medical Centre, Shinsuna Koto-ku, Tokyo, Japan.
Ikuko OginoDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Hanbing XuDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Chihiro KamoharaDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Shinya YamadaDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Kostadin KaragiozovDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Asahimachi, Niigata, Japan.
Akihide KondoDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Hajime AraiDepartment of Neurosurgery, Juntendo University, Hongo Bunkyo-ku, Tokyo, Japan.
Juntendo University · JPKoto Hospital · JPInstitute of Brain and Blood Vessels · JPNiigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe amyloid-β oligomers, consisting of 10-20 monomers (AβO10-20), have strong neurotoxicity and are associated with cognitive impairment in Alzheimer's disease (AD). However, their role in patients with idiopathic normal pressure hydrocephalus (iNPH) is poorly understood.

objectiveWe hypothesized that cerebrospinal fluid (CSF) AβO10-20 accumulates in patients with iNPH, and its clearance after CSF shunting contributes to neurological improvement. We measured CSF AβO10-20 levels before and after CSF shunting in iNPH patients evaluating their diagnostic and prognostic role.

methodsWe evaluated two iNPH cohorts: "evaluation" (cohort-1) with 32 patients and "validation" (cohort-2) with 13 patients. Comparison cohorts included: 27 neurologically healthy controls (HCs), and 16 AD, 15 Parkinson's disease (PD), and 14 progressive supranuclear palsy (PSP) patients. We assessed for all cohorts CSF AβO10-20 levels and their comprehensive clinical data. iNPH cohort-1 pre-shunting data were compared with those of comparison cohorts, using cohort-2 for validation. Next, we compared cohort-1's clinical and CSF data: 1) before and after CSF shunting, and 2) increased versus decreased AβO10-20 levels at baseline, 1 and 3 years after shunting.

resultsCohort-1 had higher CSF AβO10-20 levels than the HCs, PD, and PSP cohorts. This result was validated with data from cohort-2. CSF AβO10-20 levels differentiated cohort-1 from the PD and PSP groups, with an area under receiver operating characteristic curve of 0.94. AβO10-20 levels in cohort-1 decreased after CSF shunting. Patients with AβO10-20 decrease showed better cognitive outcome than those without.

conclusionAβO10-20 accumulates in patients with iNPH and is eliminated by CSF shunting. AβO10-20 can be an applicable diagnostic and prognostic biomarker.

Indexed as

Cerebrospinal Fluid ShuntsAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersBrain DiseasesCohort StudiesFemaleHumansHydrocephalus, Normal PressureMaleParkinson DiseaseSupranuclear Palsy, ProgressiveAmyloid beta-PeptidesBiomarkersAmyloid-β peptidesbiomarkerscerebrospinal fluidneurodegenerative diseasesnormal pressure hydrocephalus

Identifiers

PMID34275898
PMCPMC8461658
OpenAlexW3184212274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.